⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
prnewswire.com
RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com
RIGL
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight
globenewswire.com
LLY
MRK
GSK
BMY
AZN
PFE
NVO
REGN
RDHL
AGIO
INCY
CRBP
BMRN
VKTX
RIGL
DTIL
CRDF
BIIB
ALKS
EXAS
CLDX
SRPT
TGTX
ALNY
CHKP
TAK
HHS
SERV
GILD
HRMY
IONS
BH
FORM
JNJ
GEN
ABBV
AMGN
CRSP
CHRD
ADPT
IMUX
ALGN
EXEL
VRTX
Quantum Computing Market Poised for Rapid Growth Through 2031 as Enterprise Adoption, Cloud Access and Breakthrough Applications Accelerate
globenewswire.com
IBM
MSFT
INTC
RIGL
GOOG
IONQ
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Rigel to Participate in Upcoming September Investor Conferences
prnewswire.com
RIGL
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
globenewswire.com
RIGL
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
prnewswire.com
RIGL
Synthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officer
businesswire.com
RIGL
GERN
Form 8-K
sec.gov
RIGL